Search results
Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome
Benzinga via Yahoo Finance· 11 months agoEloxx Pharmaceuticals Inc (NASDAQ: ELOX) intends to advance ELX-02 into a pivotal trial for treating...
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
Zacks via Yahoo Finance· 2 years agoIt has been a busy week for the biotech companies with a plethora of important updates. Drug...
Europe to withdraw PTC Therapeutics' rare muscle disorder drug
Reuters via Yahoo News· 3 months agoThe drug, Translarna, had received conditional approval in the European Union in 2014 to treat ambulatory children aged five years and older with Duchenne muscular dystrophy (DMD) expressing ...
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Zacks via Yahoo Finance· 1 month agoIt was a busy week for the biotech sector with lots of study data readouts and regulatory approvals....
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug
Zacks via Yahoo Finance· 8 months agoPTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for...
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Zacks via Yahoo Finance· 2 months agoPTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to...
PTC Duchenne drug approval set to be revoked in Europe
BioPharma Dive via Yahoo Finance· 3 months agoEuropean authorities are set to rescind the approval of a Duchenne muscular dystrophy drug that’s...
Is PTC Therapeutics (PTCT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
GuruFocus.com via Yahoo Finance· 8 months agoValue-focused investors are always on the hunt for stocks that are priced below their intrinsic...
Duchenne Muscular Dystrophy: the global clinical trials landscape 2024
Pharmaceutical Technology via Yahoo Finance· 7 days agoAffecting muscle and skeletal strength, this rare genetic disorder impacts thousands of men...
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
Zacks via Yahoo Finance· 2 years agoEloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in...